152 related articles for article (PubMed ID: 37894375)
1. EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer.
Falkenbach F; Ambrosini F; Tennstedt P; Eiber M; Heck MM; Preisser F; Graefen M; Budäus L; Koehler D; Knipper S; Maurer T
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894375
[TBL] [Abstract][Full Text] [Related]
2. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Mehdi Irai M; Simon R; Koehler D; Rauscher I; Eiber M; van Leeuwen FWB; van Leeuwen P; de Barros H; van der Poel H; Budäus L; Steuber T; Graefen M; Tennstedt P; Heck MM; Horn T; Maurer T
Eur Urol; 2023 Jan; 83(1):62-69. PubMed ID: 35718637
[TBL] [Abstract][Full Text] [Related]
3. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support.
Falkenbach F; Knipper S; Koehler D; Ambrosini F; Steuber T; Graefen M; Budäus L; Eiber M; Lunger L; Lischewski F; Heck MM; Maurer T
World J Urol; 2023 Sep; 41(9):2343-2350. PubMed ID: 37515651
[TBL] [Abstract][Full Text] [Related]
5. Value of
Rauscher I; Düwel C; Wirtz M; Schottelius M; Wester HJ; Schwamborn K; Haller B; Schwaiger M; Gschwend JE; Eiber M; Maurer T
BJU Int; 2017 Jul; 120(1):40-47. PubMed ID: 27862863
[TBL] [Abstract][Full Text] [Related]
6.
Maurer T; Robu S; Schottelius M; Schwamborn K; Rauscher I; van den Berg NS; van Leeuwen FWB; Haller B; Horn T; Heck MM; Gschwend JE; Schwaiger M; Wester HJ; Eiber M
Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
[TBL] [Abstract][Full Text] [Related]
7. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
[TBL] [Abstract][Full Text] [Related]
8. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
de Barros HA; van Oosterom MN; Donswijk ML; Hendrikx JJMA; Vis AN; Maurer T; van Leeuwen FWB; van der Poel HG; van Leeuwen PJ
Eur Urol; 2022 Jul; 82(1):97-105. PubMed ID: 35339318
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy.
Knipper S; Ascalone L; Ziegler B; Hohenhorst JL; Simon R; Berliner C; van Leeuwen FWB; van der Poel H; Giesel F; Graefen M; Eiber M; Heck MM; Horn T; Maurer T
Eur Urol; 2021 Apr; 79(4):537-544. PubMed ID: 33317857
[TBL] [Abstract][Full Text] [Related]
11. [PSMA-radioguided surgery in localised recurrent prostate cancer].
Horn T; Rauscher I; Eiber M; Gschwend JE; Maurer T
Urologe A; 2017 Nov; 56(11):1417-1423. PubMed ID: 29022058
[TBL] [Abstract][Full Text] [Related]
12. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
[TBL] [Abstract][Full Text] [Related]
13.
Zuur LG; de Barros HA; van Oosterom MN; Berrens AC; Donswijk ML; Hendrikx JJMA; Bekers EM; Vis AN; Wit EM; van Leeuwen FB; van der Poel HG; van Leeuwen PJ
BJU Int; 2024 Feb; ():. PubMed ID: 38346924
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological predictors of positive
Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
[TBL] [Abstract][Full Text] [Related]
15. Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands.
Rauscher I; Horn T; Eiber M; Gschwend JE; Maurer T
World J Urol; 2018 Apr; 36(4):603-608. PubMed ID: 29372353
[TBL] [Abstract][Full Text] [Related]
16. Event-free survival after
Ceci F; Rovera G; Iorio GC; Guarneri A; Chiofalo V; Passera R; Oderda M; Dall'Armellina S; Liberini V; Grimaldi S; Bellò M; Gontero P; Ricardi U; Deandreis D
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3257-3268. PubMed ID: 35217883
[TBL] [Abstract][Full Text] [Related]
17. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Tilki D; Mansholt J; Berliner C; Bernreuther C; Steuber T; Maurer T; Graefen M
Eur Urol Focus; 2019 Jan; 5(1):50-53. PubMed ID: 30292421
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
Gandaglia G; Mazzone E; Stabile A; Pellegrino A; Cucchiara V; Barletta F; Scuderi S; Robesti D; Leni R; Samanes Gajate AM; Picchio M; Gianolli L; Brembilla G; De Cobelli F; van Oosterom MN; van Leeuwen FWB; Montorsi F; Briganti A
Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
20. High detection rate in [
Watabe T; Uemura M; Soeda F; Naka S; Ujike T; Hatano K; Sasaki H; Kamiya T; Shimosegawa E; Kato H; Cardinale J; Tateishi U; Nonomura N; Giesel FL
Ann Nucl Med; 2021 Apr; 35(4):523-528. PubMed ID: 33661475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
